Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.

  • STATUS
    Recruiting
  • End date
    Oct 26, 2023
  • participants needed
    1000
  • sponsor
    Hospices Civils de Lyon
Send
Updated on 26 January 2021
See if I qualify

Summary

Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide. The current strategy proposed by the EASL/EASO/EASD European guidelines for the screening of nonalcoholic fatty liver disease (NAFLD) in high-risk population such as type 2 diabetes and patients with obesity leads to an over-referral in hepatology clinics. The proposed study will investigate the optimal strategy for the screening of NAFLD-related advanced fibrosis in patients at high risk of fibrotic NAFLD, such as patients with T2DM or obesity by maximizing the positive predictive value (PPV) using non-invasive blood and elastography-based biomarkers in endocrinology/diabetology clinics in order to reduce the over-referral to hepatology clinics.

Details
Condition NAFLD, Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease, non-alcoholic fatty liver
Treatment Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
Clinical Study IdentifierNCT04435054
SponsorHospices Civils de Lyon
Last Modified on26 January 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age between 40 yrs and 80 yrs?
Gender: Male or Female
Do you have any of these conditions: Nonalcoholic Steatohepatitis (NASH) or Non Alcoholic Fatty Liver Disease or NAFLD or non-alcoholic fatty liver or Non-alcoholic Fatty Liver Disease or...?
Do you have any of these conditions: Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis (NASH) or NAFLD or Non Alcoholic Fatty Liver Disease or Non-alcoholic Fatty Liver Dis...?
Do you have any of these conditions: Nonalcoholic Fatty Liver Disease or non-alcoholic fatty liver or Non-alcoholic Fatty Liver Disease or Non Alcoholic Fatty Liver Disease or Nonalcoholi...?
Patient aged between 40 and 80 years old
Patients with diagnosis of T2DM or obesity (defined according to World Health Organization as a BMI 30 kg/m2)
Patient with hepatic steatosis determined by conventional abdominal ultrasound as defined by the EASL/EASO/EASD European guidelines
Patient who agrees to be included in the study and who signs the informed consent form
Patient affiliated to a healthcare insurance plan

Exclusion Criteria

Evidence of other causes of chronic liver disease
History of ingestion of medications known to produce steatosis in the previous 6 months
Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices
Presence of regular and/or excessive use of alcohol (defined as >30g/day for males and >15g/day for females) for a period longer than 2 years at any times in the last 10 years
The subject is a pregnant or nursing female
Life expectancy less than 5 years
History of known HIV infection
History of type 1 diabete
BMI 40 kg/m2
Mentally unbalanced patients, under supervision or guardianship
Patient deprived of liberty
Patient who does not understand French/ is unable to give consent
Patient already included in a trial who may interfere with the study or in a period of exclusion following participation in a previous study
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note